Drug Interactions between pazopanib and Votrient
This report displays the potential drug interactions for the following 2 drugs:
- pazopanib
- Votrient (pazopanib)
Interactions between your drugs
No interactions were found between pazopanib and Votrient. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
pazopanib
A total of 662 drugs are known to interact with pazopanib.
- Pazopanib is in the drug class VEGF/VEGFR inhibitors.
- Pazopanib is used to treat the following conditions:
Votrient
A total of 662 drugs are known to interact with Votrient.
- Votrient is in the drug class VEGF/VEGFR inhibitors.
- Votrient is used to treat the following conditions:
Drug and food interactions
PAZOPanib food
Applies to: pazopanib and Votrient (pazopanib)
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of pazopanib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. Although not studied, the interaction may increase the risk of QT interval prolongation and torsade de pointes arrhythmia as well as severe and fatal hepatotoxicity associated with the use of pazopanib.
ADJUST DOSING INTERVAL: Food increases the oral bioavailability of pazopanib. The mechanism of interaction is unknown. Administration of pazopanib with a high-fat or low-fat meal results in an approximately 2-fold increase in peak plasma concentration (Cmax) and systemic exposure (AUC).
MANAGEMENT: Patients treated with pazopanib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract. Pazopanib should be administered at least one hour before or two hours after a meal.
References
- "Product Information. Votrient (pazopanib)." GlaxoSmithKline (2009):
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Vegf/vegfr inhibitors
Therapeutic duplication
The recommended maximum number of medicines in the 'VEGF/VEGFR inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'VEGF/VEGFR inhibitors' category:
- pazopanib
- Votrient (pazopanib)
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.